Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
saRNA Lassa fever vaccine
- Development stage
- Unknown
- Lead developer
- Imperial College London
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The saRNA Lassa fever vaccine is a self-amplifying RNA (saRNA) prophylactic candidate developed by Imperial College London to prevent Lassa fever. Utilizing an alphavirus-derived replicon (typically from the Venezuelan Equine Encephalitis Virus), the vaccine encodes the Lassa virus glycoprotein complex (GPC) antigen alongside a viral replicase. This self-amplification mechanism allows for significantly lower RNA doses compared to conventional mRNA vaccines while maintaining high levels of antigen expression and robust immune activation. The vaccine is currently being evaluated in a Phase I clinical trial (NCT05985798) in healthy adults, where it is administered intramuscularly in a two-dose schedule. This program is part of a broader effort, supported by the Coalition for Epidemic Preparedness Innovations (CEPI), to develop rapid-response vaccine platforms against high-priority viral threats, including Ebola and Marburg viruses.
- Other names
- saRNA Lassa fever vaccine
02
Targets
GPC (Lassa virus glycoprotein complex)
Beyond the preview
Go deeper on saRNA Lassa fever vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on saRNA Lassa fever vaccine.